JPMorgan deepens bearish stance on Rovi with seventh straight short‑position increase
Executive summary: JPMorgan reported its seventh consecutive increase in short positions in the Spanish pharmaceutical company Rovi. The sustained bearish stance may exert downward pressure on Rovi’s share price and affect the Ibex pharma sub‑index, signalling ongoing investor skepticism.
Who is involved: JPMorgan, Rovi, and Spain’s securities regulator (CNMV) which monitors short‑position disclosures.
Likely next: Market participants will watch Rovi’s share price reaction and any further short‑position updates from JPMorgan in the coming weeks.
JPMorgan notified regulators of another rise in its short position in Rovi, marking the seventh consecutive increase. The move comes despite a recent rally in Rovi’s shares following its earnings release. Analysts view the continued shorting as a sign of persistent skepticism about the drugmaker’s near‑term prospects. The development adds to short‑selling pressure on one of Ibex’s pharmaceutical constituents.
Timeline
- — JPMorgan amplía su ofensiva bajista contra Rovi (Expansión)
Analysis — what this means
Sectors affected
- Pharmaceuticals (Ibex pharma sub‑index)
Key entities
Sources
- JPMorgan amplía su ofensiva bajista contra Rovi — Expansión
Related cases
- JPMorgan and Santander are spearheading a $15 billion financing effort to develop Argentina’s LNG infrastructure, signaling a major push to monetize the country’s gas reserves
- JPMorgan reports Tesla is confident in scaling Cybercab operations and views FSD V15 as a step‑change in autonomous driving technology
- JPMorgan’s withdrawal of banking services from Polymarket removes a key fiat on‑ramp for the prediction‑market platform and raises regulatory concerns
- BBVA posts 11% profit jump to €6.05 billion in H1 2026 and launches a €2 billion share‑buyback programme
- Jamie Dimon warns that markets are underestimating rapidly shifting risks, even as JPMorgan posts its best quarter ever
- South Korea’s largest bank adopts JPMorgan’s blockchain platform to streamline cross‑border trade payments, signaling growing institutional use of distributed ledger technology in Asian finance